Aljedani Safia S, Aldehaiman Abdullah, Sandholu Anandsukeerthi, Alharbi Siba, Mak Victor C Y, Wu Haiyan, Lugari Adrien, Jaremko Mariusz, Morelli Xavier, Backer Jonathan W, Ladbury John E, Nowakowski Michał, Cheung Lydia W T, Arold Stefan T
Biological and Environmental Science and Engineering Division, Computational Biology Research Center, King Abdullah University of Science and Technology (KAUST), Thuwal 2395-56900, Kingdom of Saudi Arabia.
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
bioRxiv. 2024 Apr 30:2024.04.30.591319. doi: 10.1101/2024.04.30.591319.
The phosphoinositide-3 kinase (PI3K), a heterodimeric enzyme, plays a pivotal role in cellular metabolism and survival. Its deregulation is associated with major human diseases, particularly cancer. The p85 regulatory subunit of PI3K binds to the catalytic p110 subunit via its C-terminal domains, stabilising it in an inhibited state. Certain Src homology 3 (SH3) domains can activate p110 by binding to the proline-rich (PR) 1 motif located at the N-terminus of p85. However, the mechanism by which this N-terminal interaction activates the C-terminally bound p110 remains elusive. Moreover, the intrinsically poor ligand selectivity of SH3 domains raises the question of how they can control PI3K. Combining structural, biophysical, and functional methods, we demonstrate that the answers to both these unknown issues are linked: PI3K-activating SH3 domains engage in additional "tertiary" interactions with the C-terminal domains of p85, thereby relieving their inhibition of p110. SH3 domains lacking these tertiary interactions may still bind to p85 but cannot activate PI3K. Thus, p85 uses a functional selection mechanism that precludes nonspecific activation rather than nonspecific binding. This separation of binding and activation may provide a general mechanism for how biological activities can be controlled by promiscuous protein-protein interaction domains.
磷酸肌醇-3激酶(PI3K)是一种异二聚体酶,在细胞代谢和存活中起关键作用。其失调与主要人类疾病,尤其是癌症相关。PI3K的p85调节亚基通过其C末端结构域与催化性p110亚基结合,使其稳定在抑制状态。某些Src同源3(SH3)结构域可通过与位于p85 N末端的富含脯氨酸(PR)1基序结合来激活p110。然而,这种N末端相互作用激活C末端结合的p110的机制仍不清楚。此外,SH3结构域固有的较差配体选择性引发了它们如何控制PI3K的问题。结合结构、生物物理和功能方法,我们证明这两个未知问题的答案是相关联的:激活PI3K的SH3结构域与p85的C末端结构域进行额外的“三级”相互作用,从而解除它们对p110的抑制。缺乏这些三级相互作用的SH3结构域可能仍与p85结合,但不能激活PI3K。因此,p85使用一种功能选择机制来防止非特异性激活而不是非特异性结合。这种结合与激活的分离可能为杂乱的蛋白质-蛋白质相互作用结构域如何控制生物活性提供一种通用机制。